Literature DB >> 19420176

Chronic brucellosis and persistence of Brucella melitensis DNA.

Maria Jesús Castaño1, Javier Solera.   

Abstract

After acute brucellosis infection, symptoms persist in a minority of patients for more than 1 year. Such patients are defined as having chronic brucellosis. Since no objective laboratory methods exist to confirm the presence of chronic disease, these patients suffer delays in both diagnosis and treatment. The aim of the current study was to evaluate the usefulness of quantitative real-time PCR (Q-PCR) in the diagnosis and follow-up of these patients. Thirty-five subjects with a well-documented history of brucellosis that had been diagnosed between 2 and 33 years previously were screened by Q-PCR for the presence of Brucella melitensis DNA and by serological tests and blood culture. Subjects were divided into three groups: 8 (23%) focal-disease subjects, 9 (26%) nonfocal-disease subjects with subjective complaints, such as fatigue, malaise, arthralgia, and/or myalgia, and 18 (51%) asymptomatic subjects. All (100%) focal-disease patients and symptomatic nonfocal-disease patients had at least one positive Q-PCR sample. Only six (33%) of the asymptomatic subjects had Q-PCR-positive samples (P < 0.05). Eleven patients (five focal-disease patients and six nonfocal-disease patients with subjective complaints) received therapy during the study. For those patients who completed treatment, six (60%) still had Q-PCR-positive samples at the posttreatment follow-up. The proportion of individuals with B. melitensis DNA was significantly higher for symptomatic nonfocal-disease patients than for asymptomatic subjects. Therefore, Q-PCR appears to be a useful method for identifying chronic brucellosis patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420176      PMCID: PMC2708509          DOI: 10.1128/JCM.02159-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Posttreatment follow-Up of brucellosis by PCR assay.

Authors:  P Morata; M I Queipo-Ortuño; J M Reguera; M A García-Ordoñez; C Pichardo; J D Colmenero
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Diagnostic yield of a PCR assay in focal complications of brucellosis.

Authors:  P Morata; M I Queipo-Ortuño; J M Reguera; F Miralles; J J Lopez-Gonzalez; J D Colmenero
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  PCR-Based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-Day postinfection period.

Authors:  R K Straubinger
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Specific antibody profile in human brucellosis.

Authors:  J Ariza; T Pellicer; R Pallarés; A Foz; F Gudiol
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

Review 5.  Chronic bacterial infections: living with unwanted guests.

Authors:  Douglas Young; Tracy Hussell; Gordon Dougan
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

6.  Microtiter-adapted method that facilitates the Coombs test for brucellosis.

Authors:  J R Otero; A Fuertes; E Palenque; A R Noriega
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

7.  Serum is the preferred clinical specimen for diagnosis of human brucellosis by PCR.

Authors:  L Zerva; K Bourantas; S Mitka; A Kansouzidou; N J Legakis
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 8.  Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes.

Authors:  Gerhard K M Endresen
Journal:  Rheumatol Int       Date:  2003-07-16       Impact factor: 2.631

9.  2-mercaptoethanol Brucella agglutination test: usefulness for predicting recovery from brucellosis.

Authors:  T M Buchanan; L C Faber
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

10.  Diagnosis of recent and relapsed cases of human brucellosis by PCR assay.

Authors:  Laila F Nimri
Journal:  BMC Infect Dis       Date:  2003-04-28       Impact factor: 3.090

View more
  28 in total

1.  The NOD-scid IL2rγnull Mouse Model Is Suitable for the Study of Osteoarticular Brucellosis and Vaccine Safety.

Authors:  Omar H Khalaf; Sankar P Chaki; Daniel G Garcia-Gonzalez; Thomas A Ficht; Angela M Arenas-Gamboa
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  Persistence of the bacterial pathogen Granulibacter bethesdensis in chronic granulomatous disease monocytes and macrophages lacking a functional NADPH oxidase.

Authors:  Jessica Chu; Helen H Song; Kol A Zarember; Teresa A Mills; John I Gallin
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

3.  Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge.

Authors:  Xinghong Yang; Beata Clapp; Theresa Thornburg; Carol Hoffman; David W Pascual
Journal:  Vaccine       Date:  2016-09-14       Impact factor: 3.641

4.  Association between Brucella melitensis DNA and Brucella sp. Antibodies.

Authors:  M Jesús Castaño Aroca; Elena Navarro García; Javier Solera Santos
Journal:  Clin Vaccine Immunol       Date:  2011-03-16

5.  B Cells Inhibit CD4+ T Cell-Mediated Immunity to Brucella Infection in a Major Histocompatibility Complex Class II-Dependent Manner.

Authors:  Alexis S Dadelahi; Carolyn A Lacey; Catherine A Chambers; Bárbara Ponzilacqua-Silva; Jerod A Skyberg
Journal:  Infect Immun       Date:  2020-04-20       Impact factor: 3.441

6.  Polymerase Chain Reaction-Based Assays for the Diagnosis of Active and Relapsed Cases of Human Brucellosis.

Authors:  Mohammad Reza Hasanjani Roushan; Seyed Mahmoud Amin Marashi; Zahra Moulana
Journal:  Am J Trop Med Hyg       Date:  2016-10-24       Impact factor: 2.345

7.  The Brucella abortus general stress response system regulates chronic mammalian infection and is controlled by phosphorylation and proteolysis.

Authors:  Hye-Sook Kim; Clayton C Caswell; Robert Foreman; R Martin Roop; Sean Crosson
Journal:  J Biol Chem       Date:  2013-04-01       Impact factor: 5.157

8.  Efficient diagnosis and treatment follow-up of human brucellosis by a novel quantitative TaqMan real-time PCR assay: a human clinical survey.

Authors:  Majid Sohrabi; Ashraf Mohabati Mobarez; Nima Khoramabadi; Reza Hosseini Doust; Mehrdad Behmanesh
Journal:  J Clin Microbiol       Date:  2014-10-01       Impact factor: 5.948

9.  Sustained and differential antibody responses to virulence proteins of Brucella melitensis during acute and chronic infections in human brucellosis.

Authors:  J Xu; Y Qiu; M Cui; Y Ke; Q Zhen; X Yuan; Y Yu; X Du; J Yuan; H Song; Z Wang; G Gao; S Yu; Y Wang; L Huang; Z Chen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-15       Impact factor: 3.267

10.  A potent Brucella abortus 2308 Δery live vaccine allows for the differentiation between natural and vaccinated infection.

Authors:  Junbo Zhang; Shuanghong Yin; Fei Guo; Ren Meng; Chuangfu Chen; Hui Zhang; Zhiqiang Li; Qiang Fu; Huijun Shi; Shengwei Hu; Wei Ni; Tiansen Li; Ke Zhang
Journal:  J Microbiol       Date:  2014-07-04       Impact factor: 3.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.